- Unstable because of AF? (shock, ischemia, pulmonary edema) → synchronized cardioversion ≥200 J now.
- Find the fire. Sepsis, bleed, hypovolemia, PE, pain, withdrawal, thyroid. Fast AF is often the alarm, not the fire.
- Look for pre-excitation. Very fast (>250), wide, changing QRS → no AV nodal blockers.
- Know the EF. EF >40% → metoprolol or diltiazem. EF ≤40% → no diltiazem; use amiodarone or digoxin.
- Target resting HR <110 if symptoms are controlled.
- Decide on anticoagulation today (CHA₂DS₂-VASc) — before any cardioversion, electrical or chemical.
Pathophysiology in 60 seconds
⌄
- Trigger + substrate. Ectopic beats, mostly from the pulmonary veins, start AF. Stretched, scarred atria keep it going. AF remodels the atria → AF begets AF.
- The AV node is the gatekeeper. Atria fire 350–600/min. The AV node lets only some through. Rate-control drugs act on the AV node.
- Why patients crash. Fast rate shortens diastole → less LV filling and less coronary flow. Loss of the atrial kick hurts stiff ventricles most (HFpEF, AS, HCM).
- Why strokes happen. No organized atrial contraction → stasis in the left atrial appendage → thrombus → embolism.
Rate control makes the bouncer stricter (β-blocker, diltiazem, digoxin). In pre-excited AF, block the front door and the crowd rushes the side door → VF.
The atria are a mosh pit. The AV node is the bouncer. Your drugs make the bouncer stricter. In WPW there is a side door with no bouncer — so do not block the front door.
Diagnosis & classification
⌄
| Element | Criterion |
|---|---|
| ECG | Irregularly irregular R–R, no repeating P waves |
| Duration needed | Full 12-lead, or ≥30 s on a strip |
| "RVR" | Ventricular rate >100–110/min |
2023 ACC/AHA stages: 1 At risk → 2 Pre-AF → 3A Paroxysmal (≤7 d) · 3B Persistent (>7 d) · 3C Long-standing (>12 mo) · 3D after successful ablation → 4 Permanent.
| Mimic | Clue | Why it matters |
|---|---|---|
| MAT | ≥3 P-wave shapes, COPD | Treat the lungs. No cardioversion, no OAC for MAT |
| Flutter, variable block | Sawtooth in II, III, aVF | Same OAC rules; ablation often cures |
| Sinus tach + PACs | P before each QRS | Treat the cause |
| Pre-excited AF | Very fast, wide, bizarre QRS | AV nodal blockers → VF |
Workup — and why
⌄
| Test | What it changes |
|---|---|
| 12-lead ECG | Pre-excitation, ischemia, baseline QTc |
| BMP + Mg | Replete K >4, Mg >2; CrCl for DOAC dosing |
| TSH | Thyrotoxicosis → propranolol, treat thyroid |
| CBC | Bleeding source; OAC bleeding risk |
| Troponin | Only if chest pain / ischemic ECG — a flat bump is usually demand |
| TTE | EF decides the drug; mitral stenosis / mechanical valve → warfarin |
| TEE | Before cardioversion if AF ≥48 h and no 3 weeks of OAC |
Management
⌄
| Drug | Dose | Best for | Avoid |
|---|---|---|---|
| Metoprolol tartrate | 2.5–5 mg IV over 2 min q5 min (max 15 mg); PO 25–100 mg BID | Most patients, ACS, thyroid | Decompensated HF, hypotension |
| Diltiazem | 0.25 mg/kg IV (~15–20 mg) over 2 min; repeat 0.35 mg/kg; drip 5–15 mg/h | EF >40%, COPD | EF ≤40%, hypotension |
| Esmolol | 500 mcg/kg over 1 min → 50–300 mcg/kg/min | Borderline BP | Often needs ICU |
| Digoxin | 0.25 mg IV q2h, max 1.5 mg/24 h | HFrEF, soft BP | Slow onset; CKD; with amiodarone |
| Amiodarone | 150 mg IV/10 min → 1 mg/min ×6 h → 0.5 mg/min ×18 h | Shock, HFrEF | Can cardiovert → stroke risk |
Do not stack IV diltiazem + metoprolol + amiodarone in one hour. Go oral early.
- Consider when: first symptomatic episode, HFrEF / suspected tachycardia-mediated cardiomyopathy, rate control fails, younger patient, early AF (EAST-AFNET 4).
- Cardioversion rules: AF ≥48 h or unknown → 3 weeks of OAC or TEE first. After any cardioversion → OAC ≥4 weeks.
- Drugs: amiodarone (structural disease OK) · flecainide/propafenone only without CAD/structural disease (+ AV nodal blocker) · dofetilide/sotalol need inpatient QTc monitoring.
- Ablation: first-line for selected symptomatic patients; improves outcomes in HFrEF (CASTLE-AF).
| CHA₂DS₂-VASc | Points |
|---|---|
| CHF / EF ≤40% | 1 |
| Hypertension | 1 |
| Age ≥75 | 2 |
| Diabetes | 1 |
| Stroke / TIA / embolism | 2 |
| Vascular disease | 1 |
| Age 65–74 | 1 |
| Female sex | 1 |
- ACC/AHA 2023: OAC if ≥2 (men) / ≥3 (women). ESC 2024 uses CHA₂DS₂-VA (no sex point): OAC if ≥2.
- DOAC over warfarin — except mechanical valve or moderate–severe mitral stenosis.
- Apixaban 5 mg BID; reduce to 2.5 mg if 2 of 3: age ≥80, weight ≤60 kg, Cr ≥1.5.
- HAS-BLED finds fixable bleeding risks. Falls alone rarely justify no OAC. Aspirin is not stroke prevention.
- HCM + AF → anticoagulate regardless of score.
Doses are typical adult doses with normal kidney and liver function. Check the dose in CKD, liver disease, frailty or low weight.
Pitfalls
⌄
- Shooting the fire alarm — HR 135 in septic shock is compensatory. Diltiazem → hypotension.
- Forgetting that amiodarone can cardiovert → same clot risk as DCCV.
- Diltiazem in HFrEF — negative inotrope.
- Calling every troponin bump an NSTEMI.
- Not replacing K and Mg.
- No anticoagulation plan (or insurance check) at discharge.
Board corner
⌄
| Stem clue | Answer |
|---|---|
| AF, BP 78/40, confused, HR 170 | Synchronized cardioversion now |
| Irregular, >250/min, wide QRS changing shape | Pre-excited AF → procainamide / DCCV |
| AF + EF 30% — which rate drug to avoid? | Diltiazem / verapamil |
| AF + mechanical mitral valve | Warfarin, not DOAC |
| Unknown duration, wants cardioversion | 3 weeks OAC or TEE; OAC ≥4 weeks after |
| Regular narrow tachycardia at exactly 150 | Think 2:1 atrial flutter |
| Starting amiodarone in a patient on digoxin | Cut digoxin dose |
| Life-threatening bleed on dabigatran | Idarucizumab |
Discharge checklist
⌄
- ☐ Resting HR <110 on a stable oral regimen
- ☐ Trigger found and treated (infection, thyroid, alcohol, lytes)
- ☐ TTE done or scheduled
- ☐ OAC decided, started, covered by insurance; patient taught
- ☐ Cardiology/EP follow-up in 1–2 weeks; ablation discussed
- ☐ OSA screen, weight, BP, alcohol counseling
References
⌄
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for AF. Circulation. 2024;149:e1–e156.
- Van Gelder IC, et al. 2024 ESC Guidelines for AF. Eur Heart J. 2024.
- 2025 AHA Guidelines for CPR and ECC — Adult ALS (cardioversion energies).
- RACE II (NEJM 2010) · EAST-AFNET 4 (NEJM 2020) · CASTLE-AF (NEJM 2018).